Masafumi Funamoto 1 , 2 , Yoichi Sunagawa 1 , 2 , 3 , Yasufumi Katanasaka 1 , 2 , 3 , Yusuke Miyazaki 1 , 2 , Atsushi Imaizumi 4 , Hideaki Kakeya 5 , Hajime Yamakage 2 , Noriko Satoh-Asahara 2 , Maki Komiyama 2 , Hiromichi Wada 2 , Koji Hasegawa 2 , Tatsuya Morimoto 1 , 2 , 3
26 August 2016
COPD is mainly caused by tobacco smoking and is associated with a high frequency of coronary artery disease. There is growing recognition that the inflammation in COPD is not only confined to the lungs but also involves the systemic circulation and can impact nonpulmonary organs, including blood vessels. α1-antitrypsin–low-density lipoprotein (AT-LDL) complex is an oxidatively modified LDL that accelerates atherosclerosis. Curcumin, one of the best-investigated natural products, is a powerful antioxidant. However, the effects of curcumin on AT-LDL remain unknown. We hypothesized that Theracurmin ®, a highly absorptive curcumin with improved bioavailability using a drug delivery system, ameliorates the inflammatory status in subjects with mild COPD.
This is a randomized, double-blind, parallel-group study. Subjects with stages I–II COPD according to the Japanese Respiratory Society criteria were randomly assigned to receive 90 mg Theracurmin ® or placebo twice a day for 24 weeks, and changes in inflammatory parameters were evaluated.
There were no differences between the Theracurmin ® and placebo groups in terms of age, male/female ratio, or body mass index in 39 evaluable subjects. The percent changes in blood pressure and hemoglobin A1c and LDL-cholesterol, triglyceride, or high-density lipoprotein-cholesterol levels after treatment were similar for the two groups. However, the percent change in the AT-LDL level was significantly ( P=0.020) lower in the Theracurmin ® group compared with the placebo group.